Table 1 Patient Demographic and Clinicopathologic Characteristics
Characteristic | MIMS Trial study group (n = 489) | Peripheral blood (n = 215) | Bone marrow (n = 177) |
|---|---|---|---|
Age | Â | Â | Â |
   Mean (St. Dev.) | 56.8 (11.4) | 56.3 (10.9) | 56.3 (10.8) |
   Range | 26, 89 | 29, 84 | 30, 83 |
Race | Â | Â | Â |
   Caucasian | 421 (86.1%) | 180 (83.7%) | 157 (88.7%) |
   Black | 61 (12.5%) | 31 (14.4%) | 18 (10.2%) |
   Other | 7 (1.5%) | 4 (1.9%) | 2 (1.1%) |
Primary Tumor | Â | Â | Â |
   T1 | 334 (68.3%) | 146 (67.9%) | 117 (66.1%) |
   T2 | 145 (29.7%) | 63 (29.3%) | 52 (29.4%) |
   T3 | 10 (2.1%) | 6 (2.8%) | 8 (4.5%) |
Histologic Grade | Â | Â | Â |
   I | 133 (27.2%) | 63 (29.3%) | 53 (29.9%) |
   II | 195 (39.9%) | 89 (41.4%) | 66 (37.3%) |
   III | 136 (27.8%) | 54 (25.1%) | 49 (27.7%) |
Nodal Metastases (H&E) | Â | Â | Â |
   N0 | 344 (70.4%) | 150 (69.8%) | 127 (71.8%) |
   N1 | 145 (29.7%) | 64 (29.8%) | 49 (27.7%) |
Nodal Metastases (PCR) | Â | Â | Â |
   N0 | 251 (51.3%) | 116 (54.0%) | 94 (53.1%) |
   N1 | 238 (48.7%) | 96 (44.7%) | 80 (45.2%) |
Clinical Stage: | Â | Â | Â |
   I | 267 (54.6%) | 120 (55.8%) | 97 (54.8%) |
   IIA | 138 (28.2%) | 55 (25.6%) | 47 (26.6%) |
   IIB | 69 (14.1%) | 33 (15.4%) | 25 (14.1%) |
   IIIA | 11 (2.3%) | 7 (3.3%) | 8 (4.5%) |
   IIIB | 2 (0.4%) | 0 (0%) | 0 (0%) |
   IV | 2 (0.4%) | 0 (0%) | 0 (0%) |
ER Status | Â | Â | Â |
   ER-neg | 107 (21.9%) | 46 (21.4%) | 42 (23.7%) |
   ER-pos | 360 (73.6%) | 154 (71.6%) | 122 (68.9%) |
PR Status | Â | Â | Â |
   PR-neg | 156 (31.9%) | 67 (31.2%) | 58 (32.8%) |
   PR-pos | 284 (58.1%) | 120 (55.8%) | 85 (48.0%) |
Her2neu Status | Â | Â | Â |
   Her2neu-neg | 218 (44.6%) | 115 (53.5%) | 91 (51.4%) |
   Her2neu-pos | 89 (18.2%) | 42 (19.5%) | 30 (16.9%) |
Histologic Type | Â | Â | Â |
   Infiltrating Ductal | 394 (80.6%) | 167 (77.7%) | 140 (79.1%) |
   Infiltrating Lobular | 44 (9.0%) | 18 (8.4%) | 16 (9.0%) |
   Other | 50 (10.2%) | 30 (14.0%) | 21 (11.9%) |
Risk Category | Â | Â | Â |
   Low Risk | 53 (10.8%) | 23 (10.7%) | 16 (9.0%) |
   Intermediate Risk | 50 (10.2%) | 11 (5.1%) | 13 (7.3%) |
   High Risk | 386 (78.9%) | 181 (84.2%) | 148 (83.6%) |